Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease
Chih-Cheng Lai
BackgroundChronic obstructive pulmonary disease (COPD) is a prevalent, debilitating condition linked to significant morbidity and mortality. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated clinical benefits for COPD, the effect of tirzepatide on COPD outcomes remains to be fully elucidated.MethodsThis study utilized the TriNetX Global Collaborative Network to analyze data from adults with COPD who were prescribed tirzepatide between 1 January 2022, and 28 February 20